Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test
CARLSBAD, Calif., Dec. 17, 2019 — Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned subsidiary of OraSure Technologies, Inc., announced today a collaboration to develop a new test called LifeKit® Prevent, which may represent a microbiome-driven paradigm shift in colon cancer screening. According to the American Cancer Society, colorectal cancer is the third […]
Standardization in microbiome measurements: considerations from sampling to analysis
UPDATE: On May 12, 2020, CoreBiome rebranded as Diversigen Inc. From sample collection to analysis, the ability to snapshot the microbial community and accurately analyze the results is key to the success of any study. To accomplish these feats, accurate and reproducible protocols for sample collection, DNA extraction, sequencing methodology and data interpretation are required. […]
New White Paper on Resistome Profiling
Resistome profiling poses several advantages over PCR or qPCR alone. No prior knowledge of the ARGs of interest is needed in resistome profiling as all the sequences are being compared to curated and updated reference databases. This comparison enables the simultaneous and global characterization of the potential ARGs present in the microbiome of interest. The […]
Diversigen bioinformatics team publishes review on the human virome and disease
“The virome is comprised of endogenous retroviruses, eukaryotic viruses, and bacteriophages and is increasingly being recognized as an essential part of the human microbiome. The human virome is associated with Type-1 diabetes (T1D), Type-2 diabetes (T2D), Inflammatory Bowel Disease (IBD), Human Immunodeficiency Virus (HIV) infection, and cancer. Increasing evidence also supports trans-kingdom interactions of viruses […]
“Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases”
“Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, affect several million individuals worldwide. Crohn’s disease and ulcerative colitis are complex diseases that are heterogeneous at the clinical, immunological, molecular, genetic, and microbial levels.” Read More
CoreBiome adds leading microbiome researcher Rob Knight as Scientific Advisor
Today, CoreBiome announced that leading microbiome researcher Rob Knight, Professor and Director of the Center for Microbiome Innovation at the University of California San Diego, will be joining its scientific advisory board. As an investigator on the National Institutes of Health Human Microbiome Project and a co-founder of the American Gut Project, Dr. Knight is […]
A look ahead for the microbiome industry: An interview with Dr. Dan Knights
UPDATE: On May 12, 2020, CoreBiome rebranded as Diversigen Inc. We recently introduced readers of The Microbiome Snapshot to our sister company, CoreBiome, a privately-held, Minnesota-based microbiome analysis company that accelerates discovery for customers in the pharmaceutical, agricultural, environmental and research communities. We are continuing this story via a podcast with CoreBiome co-founder, Dr. Dan Knights. In […]
